Publication | Closed Access
Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)
11
Citations
0
References
2014
Year
OncologySingle AgentMedicinePathologyAdvanced Solid TumorsAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchInhibitor Byl719
No additional data available for this publication yet. Check back later!